Raloxifene trial in postmenopausal woman with treatment-resistant schizophrenia.

Abstract

Raloxifene augmentation in postmenopausal women with schizophrenia has shown promising results. Younger patients diagnosed as treatment-resistant schizophrenia and treated with raloxifene (120 mg/day) have reported significant improvement in symptoms. This case highlights how raloxifene, a selective estrogen receptor modulator (SERM), can play a major role in alleviating positive and negative symptoms in postmenopausal women with treatment-resistant schizophrenia.

• Authors: Hema Tharoor, Aparna Goyal
• Journal: Archives of women's mental health (Arch Womens Ment Health) Vol. 18 Issue 5 Pg. 741-2 (Oct 2015) ISSN: 1435-1102 [Electronic] Austria
• PMID: 26189131 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antipsychotic Agents
• Selective Estrogen Receptor Modulators
• Raloxifene Hydrochloride

Topics

• Antipsychotic Agents (therapeutic use)
• Dose-Response Relationship, Drug
• Drug Therapy, Combination
• Female
• Humans
• Middle Aged
• Postmenopause (drug effects)
• Raloxifene Hydrochloride (administration & dosage, therapeutic use)
• Schizophrenia (drug therapy)
• Selective Estrogen Receptor Modulators (administration & dosage, therapeutic use)
• Treatment Outcome